India to Sudan: Artemether Export Trade Route

To import Artemether formulations into Sudan, the following approvals and registrations are mandatory:

1. Manufacturer Registration: The manufacturing facility must be registered with the NMPB.

2. Product Registration: The Artemether formulation must be registered and freely sold in the country of origin. If not, a justification must be provided.

3. Application Submission: An application form, completed by the applicant, must be submitted along with the prescribed fees.

The NMPB requires that the manufacturing plants be registered within their system. (nmpb.gov.sd)

Indian exporters of Artemether formulations must comply with Good Manufacturing Practice (GMP) standards recognized by the NMPB. This includes obtaining GMP certification that aligns with international guidelines to ensure product quality and safety.

These requirements are essential for the NMPB to grant permission for importation. (nmsf.gov.sd)

As of March 2026, there have been no publicly documented regulatory changes, new guidelines, mutual recognition agreements, or policy shifts specifically affecting Indian pharmaceutical exports to Sudan in the past 18 months. Importers and exporters are advised to maintain regular communication with the NMPB to stay informed about any potential updates or changes in the regulatory landscape.

Malaria remains a significant public health challenge in Sudan, with the World Health Organization (WHO) reporting approximately 1.8 million confirmed cases in 2024. The high prevalence of malaria drives substantial demand for effective treatments, notably Artemether-based formulations. In 2024, Sudan imported Artemether formulations valued at $14.7 million from India alone, indicating a heavy reliance on imports to meet domestic needs. While local pharmaceutical manufacturing exists, it primarily focuses on less complex medications, resulting in limited domestic production of advanced antimalarial formulations. Consequently, Sudan's healthcare system depends significantly on imported Artemether products to combat malaria effectively.

Sudan imposes a 0% import duty on pharmaceutical products classified under HS code 30046000, which includes Artemether formulations. This exemption is part of Sudan's policy to ensure the availability of essential medicines. Additionally, pharmaceutical imports are subject to a 17% Value Added Tax (VAT). There are no Free Trade Agreements (FTAs) between Sudan and India that specifically affect pharmaceutical tariffs, nor are there any anti-dumping duties imposed on these imports.

India is the predominant supplier of Artemether formulations to Sudan, accounting for the majority of imports in this category. Other countries, such as China and various European Union (EU) member states, also export Artemether products to Sudan, but their market shares are comparatively smaller. India's competitive advantage lies in its cost-effective manufacturing capabilities, allowing it to offer Artemether formulations at more affordable prices than many EU manufacturers. Chinese suppliers also provide competitively priced products; however, India's established trade relations and consistent supply chains with Sudanese importers contribute to its leading position in the market.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the world's generic drug supply as of 2025. The country operates over 10,800 manufacturing facilities, including more than 3,500 WHO-GMP approved plants and 750 USFDA-compliant facilities, representing the largest concentration of regulatory-approved pharmaceutical facilities outside the United States.

This extensive infrastructure enables India to manufacture a wide range of finished dosage forms containing Artemether, such as tablets, capsules, syrups, and injections. The country's cost-effective production processes, driven by economies of scale and a skilled workforce, result in competitive pricing for Artemether formulations. Additionally, India's adherence to stringent international quality standards ensures the production of high-quality pharmaceutical products.

India's Artemether formulation exports are competitively priced compared to those from China and the European Union. While specific per-unit pricing data for 2025 is not publicly available, India's cost advantages stem from its large-scale production capabilities and efficient supply chains. In terms of quality, Indian manufacturers adhere to international standards, with numerous facilities holding WHO-GMP and USFDA certifications. This compliance ensures that Indian Artemether formulations meet the quality requirements of importing countries, including Sudan.

China, historically a major producer of artemisinin-derived APIs, has faced challenges in exporting finished pharmaceutical products due to limited WHO prequalification certifications. As of 2014, only one Chinese company had obtained such certification, restricting their access to certain international markets.

European Union manufacturers are known for high-quality branded generics but often come with higher costs due to stringent regulatory requirements and higher production expenses. For Sudanese buyers, Indian Artemether formulations offer a balanced proposition of quality and affordability, with a proven track record of regulatory acceptance and supply reliability.

The India-Sudan Artemether formulation supply chain has demonstrated reliability, supported by India's substantial manufacturing capacity and adherence to international quality standards. Indian manufacturers have invested in state-of-the-art facilities with advanced packaging and cold chain capabilities to ensure product stability during transit.

As of 2025, there have been no significant reports of supply disruptions in this trade route. Indian pharmaceutical companies maintain a strong regulatory compliance track record, with numerous facilities holding WHO-GMP and USFDA certifications. To meet growing global demand, leading Indian manufacturers have undertaken capacity expansions and infrastructure enhancements, further solidifying their position as reliable suppliers of Artemether formulations.

For Sudanese buyers sourcing Artemether formulations from India, the following strategic recommendations are advised:

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Artemether formulations.

• Understand Minimum Order Quantities (MOQs): Indian suppliers typically require MOQs ranging from 10,000 to 50,000 units per order, depending on the formulation and manufacturer. Clarify these requirements during initial negotiations to align with procurement needs.

• Negotiate Favorable Payment Terms: Common payment terms in India-Sudan pharmaceutical trade include Letters of Credit (LC) and advance payments. Establish clear payment agreements to facilitate smooth transactions.

• Conduct Thorough Supplier Qualification: Evaluate potential suppliers based on their regulatory certifications (e.g., WHO-GMP, USFDA), production capacity, quality control measures, and track record of timely deliveries.

• Monitor Regulatory Compliance: Stay informed about any changes in international and local regulations affecting the importation of Artemether formulations to ensure ongoing compliance and avoid potential disruptions.

By adhering to these recommendations, Sudanese buyers can establish a robust and reliable supply chain for Artemether formulations from India, ensuring the availability of high-quality antimalarial medications for their markets.

By adhering to this comprehensive supplier qualification framework, Sudanese pharmaceutical companies can ensure the procurement of high-quality Artemether formulations from Indian manufacturers, thereby safeguarding public health and maintaining regulatory compliance.